metisiline dirençli stafilokoklarda glikopeptid antibiyotiklere duyarlılık ...

49
69. Kato D, Ito T, Imai D, Hiramatsu K. In vitro synergy between linezolid and
sulbactam/ampicillin against methicillin-resistant Staphylococcus aureus clinical isolates
including those with reduced susceptibility to vancomycin. 40th Interscience Conference on
Antimicrobial Agents and Chemotherapy 2000; Abstract no. 2297.
70. Fridkin SK. Vancomycin-intermediate and -resistant Staphylococcus aureus: What
the infectious disease specialist needs to know. Clinical Infectious Diseases 2001; 32 (1):
108–15
71. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman
L, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358
(9277): 207–208.
72. Rybak MJ, Hershberger E, Moldovan T, Grucz RG. In vitro activities of
daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and
Enterococci, including vancomycin- intermediate and -resistant strains. Antimicrobial Agents
and Chemotherapy 2000; 44 (4): 1062–66.
73. Ruef C. Epidemiology and clinical impact of glycopeptide resistance in
Staphylococcus aureus. Infection 2004; 32: 315–27.
74. Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P, et al.
Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus
aureus with reduced vancomycin susceptibility. Clinical Infectious Diseases 2004; 38 (4):
521–28.
75. Heym B, Le Moal M, Armand-Lefevre L, Nicolas-Chanoine MR. Multilocus
sequence typing (MLST) shows that the 'Iberian' clone of methicillin-resistant
Staphylococcus aureus has spread to France and acquired reduced susceptibility to
teicoplanin. Journal of Antimicrobial Chemotherapy 2002; 50 (3): 323–29.
76. Tanaka M, Wada N, Mori-Kurosaka S, Chiba M, Sato K, Hiramatsu K. In-vitro
activity of DU-6859a against methicillin-resistant Staphylococcus aureus isolates with
reduced susceptibilities to vancomycin. J Antimicrob Chemother 1998; 42: 552–53.
77. Tenover FC, Lancaster MV, Hill BC, Steward CD, Stocker SA, Hancock GA, et
al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other
glycopeptides. J Clin MicrobioI 1998;36(4): 1020–7.
78. Chadwick PR, Wooster SL. Glycopeptide resistance in Staphylococcus aureus. J
Infect 2000; 40(3): 211–7.
79. Clinical and Laboratory Standards Institute. Antimikrobik Duyarlılık Testleri İçin
Uygulama Standartları 17.Bilgi eki Ocak 2007.
80. Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan AP. A
modified population analysis profile (PAP) method to detect hetero-resistance to
vancomycin in Staphylococcus aureus in a UK hospital. Journal of Antimicrobial
Chemotherapy 2001; 47: 399–403.
81. Van Griethuysen A, Van ’T Veen A, Buiting A, Walsh T, And Kluytmans J. High
Percentage Of Methicillin-Resistant Staphylococcus Aureus Isolates With Reduced
Susceptibility To Glycopeptides İn The Netherlands. Journal Of Clinical Miıcrobiology,
June 2003; 2487–91.
82. Spink WW, Ferris V. Quantitative action of penicillin inhibitor from penicilin
resistant strains of staphylococci. Science 1945; 102:221.